TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Ligand Pharmaceuticals
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

Insights
LGND   positive

Company projected strong revenue growth, increased royalty revenue, and robust investment strategy for 2026